ML-180 is an inverse agonist of liver receptor homolog-1 (LRH-1, IC50 = 3.7 μM) with maximum efficacy of 64% repression. It is inactive at the related steroidogenic factor-1 transcriptional activator. Through LRH-1, ML-180 alters the expression of haptoglobin and serum amyloid proteins A1 and A4, induces the death of estrogen-receptor negative MDA-MB-231 breast cancer cells, and inhibits the steroidogenic acute regulatory promoter (IC50 = 2.05 μM).
